Search results
Results from the WOW.Com Content Network
Dopamine, sold under the brand name Intropin among others, is a medication most commonly used in the treatment of very low blood pressure, a slow heart rate that is causing symptoms, and, if epinephrine is not available, cardiac arrest. [4] In newborn babies it continues to be the preferred treatment for very low blood pressure. [5]
Metaraminol is given intravenously as either a bolus (often 0.5–1 mg doses) or as an infusion, usually via peripheral intravenous access. Metaraminol is commonly available as 10 mg in 1 mL, that requires dilution prior to administration (often made up to a 0.5 mg/mL solution), however pre-prepared syringes of metaraminol for bolus use for ...
Isoprenaline is used to treat heart block and episodes of Adams–Stokes syndrome that are not caused by ventricular tachycardia or fibrillation, in emergencies for cardiac arrest until electric shock can be administered, for bronchospasm occurring during anesthesia, and as an adjunct in the treatment of hypovolemic shock, septic shock, low cardiac output (hypoperfusion) states, congestive ...
It is thought that the therapeutic effects of docarpamine are mediated by activation of peripheral dopamine D 1 receptors. [ 3 ] Although docarpamine is orally active and can achieve therapeutic levels of dopamine in blood, [ 1 ] relatively high doses and frequent administration of the drug (e.g., 600–750 mg every 8 hours) are required when ...
Transvenous cardiac pacing (TVP), [1] also called endocardial pacing, is a potentially life-saving intervention used primarily to correct profound bradycardia.It can be used to treat symptomatic bradycardias that do not respond to transcutaneous pacing or to drug therapy.
[11] [47] Hypotension is corrected with fluid replacement, although catecholamines such as norepinephrine or dopamine may be required to increase blood pressure. [13] Bradycardia is treated with atropine or an infusion of norepinephrine to increase coronary blood flow and heart rate. [13]
A dopamine reuptake inhibitor (DRI) is a class of drug which acts as a reuptake inhibitor of the monoamine neurotransmitter dopamine by blocking the action of the dopamine transporter (DAT). Reuptake inhibition is achieved when extracellular dopamine not absorbed by the postsynaptic neuron is blocked from re-entering the presynaptic neuron.
Droxidopa was developed by Sumitomo Pharmaceuticals for the treatment of hypotension, including NOH, [7] and NOH associated with various disorders such as MSA, FAP, and PD, as well as IDH. The drug has been used in Japan and some surrounding Asian areas for these indications since 1989. [7]